FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
CURE1d
FDA Approves Gozellix for Advanced PSMA-PET Imaging in Prostate Cancer
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...
Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval
Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...
Telix shares slip 11% from highs. Time to buy this high flying biotech?
Telix shares have slipped from their previous highs as global markets take a hit. Is now the time to pounce? Let's see.
Lantheus price target lowered to $122 from $127 at B. Riley
B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...
Oncology Nursing News1d
FDA Approves TLX007-CDx for Prostate Cancer Imaging
TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...
Up 113% in a year, guess which ASX 200 healthcare stock just scored another FDA win
The S&P/ASX 200 Index (ASX: XJO) healthcare stock is charging higher again on Friday following another FDA goal.
BioWorld1d
Have kit, will travel further: Telix PET-imaging agent approved by FDA
The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...